Join us for a beautiful evening with friends for breast cancer awareness month- Thursday 29 October.
Book now to avoid disappointment.
Breast cancer is one of the most common cancers in women with 20,000 new cases diagnosed in Australia each year. It is the second most common cause of cancer related deaths in women with over 3,100 deaths per year.
The team at the Fiona Elsey Cancer Research Institute are investigating Triple negative breast cancers (TNBC) which account for 10%–20% of breast cancers.
TNBCs are more aggressive and associated with poorer survival than the other subtypes of breast cancers. New treatment strategies are urgently warranted to improve TNBC patient outcomes.
Our team was the ﬁrst to report and gained national attention in findign that a pregnancy associated plasma protein (PAPPA) is highly found in aggressive TNBC (Scientiﬁc Reports, 2020). High PAPPA concentrations are generally detected in blood of pregnant women. However, in breast cancer patients, we found that an abnormal overexpression of PAPPA negatively aﬀects survival rates and increases the risk of the cancer recurring. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.
This research has provided evidence that could lead to a potential therapeutic target for the subset of breast cancers with elevated levels of the plasma protein that will improve treatment outcomes for these patients.